Merck has discontinued development of nemtabrutinib (also known as MK-1026 and formerly ARQ 531), an experimental oral BTK inhibitor for blood cancers. The decision followed a review of the Phase 3 BELLWAVE-011 trial in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). An independent monitoring committee concluded that the drug’s potential benefits might not outweigh its risks; Merck said its own review confirmed the concern. Merck is also ending the related Phase 3 trials BELLWAVE-008 and BELLWAVE-010, bringing the broader BELLWAVE program to a halt. The company has not publicly detailed the specific data behind the benefit-risk assessment. Nemtabrutinib was the centerpiece of Merck’s roughly $2.7 billion acquisition of ArQule, announced in 2019. The drug’s prospects had faded amid delays and competition from other BTK inhibitors. Sources: Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns Merck axes $2.7B BTK inhibitor pro...
- Get link
- X
- Other Apps